Advances in Glioblastoma: From Biology to Therapeutics

Topic Information

Dear Colleagues,

Glioblastoma is the most common malignant brain tumor. Despite all efforts to combat it, the average life expectancy after diagnosis is between 12 and 15 months. It is a very heterogeneous tumor at the cellular and molecular levels. Its complexity has led to it being classified according to the WHO repeatedly, first as primary—or de novo—and secondary glioblastoma, and subsequently as one of four molecular types of glioblastoma (proneural, classic, neural, and mesenchymal); finally, it is taken into account whether glioblastoma presents IDH mutations or not . Treatment with surgery, radiotherapy, and temozolomide—when the MGMT enzyme is not expressed—is what the clinic can offer today to patients with glioblastoma. This Topic accepts manuscripts that show advances in the knowledge of glioblastoma, from a biological, genetic, and pathological point of view, especially when such advances have a translational effect at the clinical level. A special mention must be made regarding brain tumor stem cells, since they are considered the initiators and maintainers of the tumor. They are highly tumorigenic and cause resistance to chemotherapy and radiotherapy, thus complicating the comprehensive treatment of this pathology. We also hope to publish articles on liquid biopsy, epigenetic etiology and treatments, studies in organoids, mesenchymal stem cells, and the role of artificial intelligence in pathology and neurosurgery. This Topic will include both original research articles and reviews.

Prof. Dr. Javier S. Castresana
Prof. Dr. Miguel Idoate
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomolecules biomolecules	4.8	9.4	2011	18.4 Days	CHF 2700	Submit
Cancers cancers	4.5	8.0	2009	17.4 Days	CHF 2900	Submit
Cells cells	5.1	9.9	2012	17 Days	CHF 2700	Submit
Organoids organoids	-	-	2022	19.3 Days	CHF 1000	Submit
Current Oncology curroncol	2.8	3.3	1994	19.8 Days	CHF 2200	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers